Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR) * Adults ≥18 years of age with either CTCL or ATLL; * AlloHCT performed from January 2012 onward. Exclusion Criteria: • Patients without consent for research.
About the study
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
Sponsor: Kyowa Kirin, Inc. · Participants: 150 · Started: Sep 10, 2019
Contact the study team
- Linda J Burns, MD · Phone: 414-805-0714
- Jatin Jadwani, BDS, MSc Clinical Research · Phone: +49 15114861167
Official record on ClinicalTrials.gov — NCT04014374
Locations in the U.S.
| Wisconsin | CIBMTR, Milwaukee |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.